Structural insight into rabies virus neutralization revealed by an engineered antibody scaffold
Kedari, Ashwini; Iheozor-Ejiofor, Rommel; Salminen, Petja; Uğurlu, Hasan; Mäkelä, Anna R.; Levanov, Lev; Vapalahti, Olli; Hytönen, Vesa P.; Saksela, Kalle; Rissanen, Ilona (2024)
Kedari, Ashwini
Iheozor-Ejiofor, Rommel
Salminen, Petja
Uğurlu, Hasan
Mäkelä, Anna R.
Levanov, Lev
Vapalahti, Olli
Hytönen, Vesa P.
Saksela, Kalle
Rissanen, Ilona
2024
Structure
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-2024121211028
https://urn.fi/URN:NBN:fi:tuni-2024121211028
Kuvaus
Peer reviewed
Tiivistelmä
Host-cell entry of the highly pathogenic rabies virus (RABV) is mediated by glycoprotein (G) spikes, which also comprise the primary target for the humoral immune response. RABV glycoprotein (RABV-G) displays several antigenic sites that are targeted by neutralizing monoclonal antibodies (mAbs). In this study, we determined the epitope of a potently neutralizing human mAb, CR57, which we engineered into a diabody format to facilitate crystallization. We report the crystal structure of the CR57 diabody alone at 2.38 Å resolution, and in complex with RABV-G domain III at 2.70 Å resolution. The CR57−RABV-G structure reveals critical interactions at the antigen interface, which target the conserved “KLCGVL” peptide and residues proximal to it on RABV-G. Structural analysis combined with a cell-cell fusion assay demonstrates that CR57 effectively inhibits RABV-G-mediated fusion by obstructing the fusogenic transitions of the spike protein. Altogether, this investigation provides a structural perspective on RABV inhibition by a potently neutralizing human antibody.
Kokoelmat
- TUNICRIS-julkaisut [23480]